Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases

Journal of Diabetes Investigation
Satoshi YoshijiNobuya Inagaki

Abstract

Bullous pemphigoid (BP) is an autoimmune blistering skin disorder. Recently, BP induced by dipeptidyl peptidase-4 (DPP-4) inhibitors has been a concern. Although DPP-4 inhibitors are commonly used in the Asian population because of their safety and efficacy, BP associated with DPP-4 inhibitors is sometimes seen in clinical settings. Here, we report five Japanese cases of BP associated with the agents. In the present cases, BP occurred in older adults using four different DPP-4 inhibitors, which showed various clinical manifestations in terms of latency period for BP, sex, glycemic control and diabetes duration. Withdrawal of DPP-4 inhibitors was effective in improving BP, and achieved remission even in cases requiring oral steroid administration and intravenous immunoglobulin therapy. Clinicians should note the importance of early diagnosis of this clinical condition and initiate prompt withdrawal of DPP-4 inhibitors.

References

May 1, 1989·The Journal of Clinical Investigation·J R Stanley
Jun 27, 1998·Clinics in Dermatology·S Vassileva
Oct 25, 2011·Diabetes Research and Clinical Practice·Yi-Ming MuKevin E K Tan
Apr 1, 2016·The British Journal of Dermatology·J BénéUNKNOWN French Association of Regional PharmacoVigilance Centres
Oct 25, 2016·The Journal of Investigative Dermatology·Kentaro IzumiHiroshi Shimizu
Sep 7, 2016·Geriatrics & Gerontology International·Taro KojimaUNKNOWN Working Group on Guidelines for Medical Treatment and its Safety in the Elderly

❮ Previous
Next ❯

Citations

Oct 27, 2018·American Journal of Clinical Dermatology·Patrick M JedlowskiMaryam T Fazel
Oct 15, 2018·Postgraduate Medical Journal·Ankur GulianiDavinder Parsad
Apr 17, 2019·Journal of Diabetes Investigation·Takaaki MurakamiNobuya Inagaki
Oct 2, 2019·BMJ Case Reports·Hariharasudan ManiAdedayo A Onitilo
Jun 9, 2018·Frontiers in Immunology·Olivier GaudinCatherine Prost-Squarcioni
Jul 6, 2019·Frontiers in Immunology·Kaisa TasanenWataru Nishie
Oct 15, 2020·Biomolecules·Francesco MoroGiovanni Di Zenzo
Nov 2, 2020·Experimental Dermatology·Payal M PatelKyle T Amber
May 25, 2021·Experimental Dermatology·Lula María Nieto-BenitoRicardo Suárez-Fernández
May 18, 2021·Journal of Diabetes Investigation·Tomonori SekizakiTatsuya Atsumi

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.